BHR-100: Completed Phase III enrollment

Besins' BHR Pharma LLC subsidiary completed enrollment of 1,180 patients in the double-blind, placebo-controlled, international Phase III SyNAPSe trial evaluating a 5-day continuous IV infusion of BHR...